Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection

Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection

Abstract The objective of this randomized controlled trial (RCT) was to assess the impact of rifaximin on the course of liver function, liver regeneration and volumetric recovery in patients undergoing major hepatectomy. The ARROW trial was an investigator initiated, single-center, open-label, phase...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jan Bednarsch, Zoltan Czigany, Sven H. Loosen, Lara Heij, Lorenz Ruckgaber, Henning Maes, Jan-Pit Krause, Matthias Reen, Beata Toteva, Theresa Vosdellen, Philipp Bruners, Sven Arke Lang, Tom Florian Ulmer, Christoph Roderburg, Tom Luedde, Ulf Peter Neumann
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/580da29a8174461383f251263e367a78
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/580da29a8174461383f251263e367a78

Documents similaires